Cytokinetics Inc vs Carparts.Com Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Carparts.Com Inc trades at $8.59 (market cap $67.00M). The key difference: Cytokinetics Inc is far larger — about 126.9× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Carparts.Com Inc for 45 Days on average.
| CYTK | PRTS | |
|---|---|---|
Market Cap | $8.50B | $67.00M |
Volume | 2,395,556 | 50,584 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $10.00 |
52-Week Low | $54.76 | $3.88 |
Typical Hold Time | 19 Days | 45 Days |
Enterprise Value | $8.60B | $79.96M |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
CarParts.com (PRTS) trades at $8.59, down 0.23% with a bullish technical outlook. The company shows improving quarterly earnings beats but faces fundamental challenges with negative profitability metrics. Recent news highlights the company's focus on leveraging proprietary data as a competitive advantage. Technical indicators show strong moving average support while oscillators remain neutral.
The stock presents a mixed picture with strong analyst support (60% buy ratings) but persistent negative earnings. Investment opportunity lies in continued operational improvements and data-driven strategy execution, while risks include sustained negative cash flow and competitive pressures in the auto parts e-commerce sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →